Skip to main content

Advertisement

SpringerLink
Log in

ASAS-Empfehlungen zur Anwendung von TNF-Blockern bei Patienten mit axialer Spondyloarthritis

Evaluation des Updates von 2010 im deutschsprachigen Raum

ASAS recommendations on the use of TNF inhibitors for patients with axial spondyloarthritis

Evaluation of the 2010 update in the German-speaking area

  • Originalien
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

Zusammenfassung

Die ASAS-Empfehlungen zur Anwendung von Tumor-Nekrose-Faktor(TNF)-Blockern bei Patienten mit axialer Spondyloarthritis sind im Jahr 2010 überarbeitet worden. Es sind wesentliche Neuerungen in das Update eingeflossen. Die Diagnose ist von der ankylosierenden Spondylitis (AS) auf die gesamte Patientengruppe der axialen Spondyloarthritis erweitert worden. Es ist eine Vorbehandlung mit mindestens zwei nichtsteroidalen Antiphlogistika (NSAR) für 4 Wochen vorgesehen. Der Therapieerfolg der Therapie mit TNF-Blocker wird nach mindestens 12 Wochen erhoben.

Im vorliegenden Bericht werden die Ergebnisse der Evaluation der deutschen Übersetzung dieser Empfehlungen vorgestellt. Insgesamt 25 Experten aus Deutschland, Österreich und der Schweiz haben die Übersetzung hinsichtlich eines Empfehlungsgrades auf einer Skala zwischen 0 (keine Übereinstimmung) bis 10 (volle Übereinstimmung) bewertet. Die Übereinstimmung der Experten mit den Empfehlungen war mit 8,96 ± 1,25 insgesamt sehr hoch.

Abstract

The ASAS recommendations on the use of tumor necrosis factor (TNF) inhibitors for patients with axial spondyloarthritis were amended in 2010. Essential new aspects have been included in the update. The diagnosis is extended from patients with ankylosing spondlitis (AS) to all patient groups of axial spondyloarthritis. Pretreatment with at least two non-steroidal anti-rheumatic drugs (NSARD) for 4 weeks is recommended. The success of therapy with TNF inhibitors is to be compiled after at least 12 weeks.

This article presents the results of the evaluation of the German translation of these recommendations. A total of 25 experts from Germany, Austria and Switzerland have scored the translation on a scale between 0 (no agreement) and 10 (full agreement) with respect to the recommendation grade. The agreement on the recommendations between the experts was very high (8.98 ± 1.25).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Abbreviations

AS:

Ankylosierender Spondylitis

ASAS:

Assessment of SpondyloArthritis International Society

AxSpA:

Axiale Spondyloarthritis

DMARDs:

Disease modifying anti-rheumatic drug

nr-axSpA:

Nichtröntgenologische axiale Spondyloarthritis

NSAR:

Nichtsteroidales Antirheumatikum

SIG:

Sakroiliakalgelenke

SpA:

Spondyloarthritis

Literatur

  1. Braun J et al (2003) International ASAS consensus statement for the use of anti-tumuor necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 62:817–824

    Article  PubMed  CAS  Google Scholar 

  2. Braun J et al (2006) First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 65:316–320

    Article  PubMed  CAS  Google Scholar 

  3. Heijde D van der (2011) 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 70:905–908

    Article  PubMed  Google Scholar 

  4. Berg van den, Baraliakos X, Braun J et al (2012) First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. J Rheumatol [ahead of print]

  5. The AGREE Collaboration (2001) Appraisal and Guidelines for Research and Evaluation. (AGREE) Instrument. http://www.agreecollaboration.org. Zugegriffen: 10. Juni 2012

  6. Rudwaleit M et al (2009) The development of Assessment of SpondyloArthritis international Society classification for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68:777–783

    Article  PubMed  CAS  Google Scholar 

  7. Braun J et al (2011) 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis (AS). Ann Rheum Dis 70:896–904

    Article  PubMed  CAS  Google Scholar 

  8. Van der Linden S et al (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361–368

    Article  Google Scholar 

  9. Gossec L, Dougados M, Phillip C et al (2008) Dissemination and evaluation of the ASAS/EULAR recommendations for the management of ankylosing spondylitis: results of a study among 1507 rheumatologists. Ann Rheum Dis 67:782–788

    Article  PubMed  CAS  Google Scholar 

  10. Rudwaleit M et al (2009) The early disease stage in axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum 60:717–727

    Article  PubMed  CAS  Google Scholar 

  11. Kiltz U, Baraliakos X, Karaklostas P et al (2012) Patients with non-radiographic axial spondyloarthritis differ from patients with ankylosing spondylitis in several aspects. Arthritis Care Res. doi:10.1002/acr.21688. [Epub ahead of print]

  12. Haibel H et al (2008) Efficacy of adalimumab in the treatment of axial spondyloarthritis without radiographically defined sacroiliitis: results of a twelve week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 58:1981–1991

    Article  PubMed  CAS  Google Scholar 

  13. Barkham N et al (2009) Clinical and images efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum 60:946–954

    Article  PubMed  CAS  Google Scholar 

  14. Rudwaleit M, Jurik AG, Hermann KG et al (2009) Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis 68(10):1520–1527

    Article  PubMed  CAS  Google Scholar 

  15. Hermann KG, Baraliakos X, Heijde DM van der et al (2012) Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI study group. Ann Rheum Dis [Epub ahead of print]

  16. Van der Heijde D et al (2005) Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 52:1205–1215

    Article  Google Scholar 

  17. Sieper J et al (2008) Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomized, double-blind, controlled study. Ann Rheum Dis 67:323–329

    Article  PubMed  CAS  Google Scholar 

  18. Garrett S et al (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286–2291

    PubMed  CAS  Google Scholar 

  19. Heijde D van der, Bellamy N, Calin A et al (1997) Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J Rheumatol 24:2225–2229

    PubMed  Google Scholar 

  20. Baraliakos X, Lisitng J, Fritz C et al (2011) Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years–early clinical response predicts long-term outcome. Rheumatology 50:1690–1696

    Article  PubMed  CAS  Google Scholar 

  21. Furst DE et al (2010) Updated consensus statement on biologoical agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis 69(Suppl 1):i2–29

    Article  PubMed  CAS  Google Scholar 

  22. Van der Heijde D et al (2008) Radiographic progression of ankylosing spondylitis after up tot wo years of treatment with etanercept. Arthritis Rheum 58:1324–1331

    Article  Google Scholar 

  23. Van der Heijde D et al (2008) Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 58:3063–3070

    Article  Google Scholar 

  24. Van der Heijde D et al (2009) Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 11:R127

    Article  Google Scholar 

Download references

Danksagung

Xenofon Baraliakos, Beat Michel, Heinrich Böhm, Jan Brandt, Cem Gabay, Winfried Graininger, Michael Hammer, Kirsten Karberg, Herbert Kellner, Lars Köhler, Klaus Krüger, Jens Kuipers, Heinz-Jürgen Lakomek, Burkhard Leeb, Elisabeth Märker-Hermann, Bernhard Manger, Wilfried Mau, Denis Poddubnyy, Stefan Rehart, Martin Rudwaleit, Michael Schirmer, In-Ho Song, Peter Villiger, Ueli Weber, Jürgen Wollenhaupt.

Interessenkonflikt

Keine Angaben.

Author information

Authors and Affiliations

  1. Rheumazentrum Ruhrgebiet, Landgrafenstr. 15, 44652, Herne, Deutschland

    U. Kiltz,  J. Sieper &  J. Braun

Authors
  1. U. Kiltz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Sieper
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Braun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to U. Kiltz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kiltz, U., Sieper, J. & Braun, J. ASAS-Empfehlungen zur Anwendung von TNF-Blockern bei Patienten mit axialer Spondyloarthritis . Z. Rheumatol. 72, 81–88 (2013). https://doi.org/10.1007/s00393-012-1089-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-012-1089-2

Schlüsselworte

Keywords

Search

Navigation